Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results
Date:5/8/2013

arter was $16.5 million, or $0.12 per share, compared with a net loss of $17.0 million, or $0.13 per share, for the same period in fiscal 2012.

Fiscal 2013 Six-Month Results

  • Total net revenues for the first six-months of fiscal 2013 totaled $34.0 million, compared with $17.2 million for the first six months of fiscal 2012.
  • Total operating expenses, excluding cost of sales and share-based compensation were $55.4 million in the first six-months of fiscal 2013, compared to $47.0 million in the comparable period for fiscal 2012.
  • Cash used in operations was $22.3 million in the first six months of fiscal 2013.
  • Net loss for the first six-months of fiscal 2013 was $28.6 million, or $0.21 per share, compared with a net loss of $33.0 million, or $0.25 per share for the comparable period in fiscal 2012.
  • NUEDEXTA Revenue
    For the quarter ended March 31, 2013, the company reported NUEDEXTA gross and net revenue of $20.8 million and $16.5 million respectively. Second quarter fiscal 2013 NUEDEXTA net revenue increased 81% versus the previous year and 11% over the previous quarter.

    Cash, Cash Equivalents & Marketable Securities
    As of March 31, 2013 Avanir had cash, cash equivalents and restricted investments totaling $70.2 million, including cash and cash equivalents of $67.9 million.

    Business Highlights

  • The company reported an eighth consecutive quarter of NUEDEXTA unit growth in both business channels with 13% retail and 4% institutional growth.
  • The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for NUEDEXTA, recommending it be approved in two dosage strengths for the treatment of pseudobulbar affect (PBA), irrespective of neurologic cause.
  • The company appointed Corinne Nevinny, a seasoned life sciences executive with broad healthcare industry experience, to the company's board of directors.
  • N
    '/>"/>

    SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
    2. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
    3. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
    4. AVANIR Pharmaceuticals To paticipate in two conferences in March
    5. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
    6. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
    7. Avanir Pharmaceuticals Announces Date Of Fiscal 2013 First Quarter Financial Results And Conference Call
    8. Avanir Pharmaceuticals Reports Fiscal 2012 Fourth Quarter And Year-End Financial And Business Results
    9. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
    10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
    11. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
    (Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
    (Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
    Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
    ... (Nasdaq: BNVI ) today announced the publication of ... to glucose limitation" in the journal Cell Cycle . ... the protein CC3/TIP30 in cancer cells and their ability to ... glucose and other nutrients. Lack of CC3/TIP30 in a variety ...
    ... 15, 2010 On June 13-14, 2011, in Beijing, China, ... historic conference on food and drug law, regulation and policy ... from China, including Shao Mingli, Commissioner, State Food and Drug ... have been invited to speak at the meeting. Several U.S. ...
    Cached Medicine Technology:Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors 2Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors 3Food and Drug Law Institute to Hold Historic Conference on U.S.-China Food and Drug Law 2
    (Date:4/24/2014)... the relevance of palliation in advanced cancer are ... trials (RCTs). This is the result of an ... Efficiency in Health Care (IQWiG), which has now ... external experts, IQWiG analysed studies on four solid ... and pancreatic cancer. For this purpose, the research ...
    (Date:4/24/2014)... has been awarded one of 30 grants from the ... Academic Participating Site in its new National Clinical ... select groups of investigators charged with distributing resources in ... NCTN grant system reflects recommendations from a 2010 ... achieve four goals:, Faster design, launch, and ...
    (Date:4/23/2014)... by Massachusetts General Hospital (MGH) investigators may lead to ... a serious medical problem use of fecal material ... the Clostridium difficile ( C. difficile ) ... the journal Clinical Infectious Diseases , the researchers ... donors unrelated to patients was as successful in curing ...
    (Date:4/23/2014)... National Institute of Arthritis and Musculoskeletal and Skin Diseases ... Ross Prize in Molecular Medicine, conferred by the Feinstein ... award will be given on June 9 at the ... scientific presentations by Dr. O,Shea and other prominent researchers. ... , The award, which includes a $50,000 prize from ...
    (Date:4/23/2014)... identified an important enzyme pathway that helps prevent new ... a condition that has been directly linked to cancer ... biochemistry, found that near the end of cell division, ... any breaks in DNA are fully repaired before the ... cells. This process helps safeguard against some of the ...
    Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
    ... of medical miracles and the very latest in scientific ... (FBR) announced today it will distribute its free daily ... experiencing tremendous success in select markets. The Animal ... medical miracles and latest scientific breakthroughs. The host ...
    ... the University of Exeter reveals for the first ... physical exercise, may help reduce cigarette cravings. Published ... shows how exercise changes the way the brain ... for nicotine. For the first time, researchers used ...
    ... Erdman, A Cogdell Spencer,Company is pleased to ... earned the U.S. Environmental Protection Agency,s (EPA,s),prestigious ENERGY ... environmental protection. America,s commercial buildings and industrial,plants that ... facilities for energy,efficiency may qualify for the ENERGY ...
    ... Help Set Unprecedented NumbersVIRGINIA BEACH, Va., Feb. 10 ... able to save the lives of 406 people ... 2008.LifeNet Health saw a 13% increase from 2007 ... to hospitals and physicians. LifeNet Health provided ...
    ... Samples taken from the 39 hunter-killed elk during ... negative for chronic wasting disease (CWD), according to ... veterinarian. Samples also tested negative for brucellosis ... is awaiting the results of CWD testing for ...
    ... China Sky One,Medical, Inc. (,China Sky One Medical, ... a,leading fully integrated pharmaceutical company producing over-the-counter,drugs in ... its,revenue and net income guidance for the full-year ... to continued strong organic growth and contribution from ...
    Cached Medicine News:Health News:Foundation for Biomedical Research Announces National Distribution of Daily Radio Broadcast 2Health News:First brain study reveals benefits of exercise on quitting smoking 2Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 2Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 3Health News:Erdman, A Cogdell Spencer Company Earns the ENERGY STAR(R) for Superior Energy 4Health News:LifeNet Health Announces a Record Year of Saving Lives and Restoring Health 2Health News:LifeNet Health Announces a Record Year of Saving Lives and Restoring Health 3Health News:Hunter-Killed Elk Test Negative for CWD and Other Diseases 2Health News:Hunter-Killed Elk Test Negative for CWD and Other Diseases 3Health News:Hunter-Killed Elk Test Negative for CWD and Other Diseases 4Health News:Hunter-Killed Elk Test Negative for CWD and Other Diseases 5Health News:China Sky One Medical, Inc. Reaffirms Guidance for 2008 Revenue and Net Income and Provides Business Update 2Health News:China Sky One Medical, Inc. Reaffirms Guidance for 2008 Revenue and Net Income and Provides Business Update 3
    ... part of the AXIOM family, which ... the clinical angiography, card- angiography, and ... functional and business pages you can ... delivers unrivalled value to users and ...
    Spring Type with lock. Titanium....
    .60 x 22mm, angled 60, .33mm end port [Simcoe]...
    ... The STARFlex is a fourth generation ... CardioSEAL by the addition of a unique ... coil micro-spring. The micro-spring is attached to ... and provides a self-adjusting positioning mechanism which ...
    Medicine Products: